J Urol 2006, 176:500–504.PubMed 49. Meyskens FL Jr, McLaren CE, Pelot D,
Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al.: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 2008, 1:32–38. 50. Quemener V, Moulinoux JP, Havouis R, Seiler N: Polyamine deprivation enhances antitumoral efficacy of chemotherapy. Anticancer Res 1992, 12:1447–1453.PubMed 51. Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW: Levels of rectal mucosal KU-57788 mw polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology 2010, 139:797–805. 805 e791PubMed 52. Levin VA, selleck chemicals llc Hess KR, Choucair A, Flynn PJ, Jaeckle KA, MLN2238 clinical trial Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, et al.: Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV
versus PCV for anaplastic gliomas. Clin Cancer Res 2003, 9:981–990.PubMed 53. Jun JY, Griffith JW, Bruggeman R, Washington S, Demers LM, Verderame MF, Manni A: Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat 2008, 107:33–40.PubMed
54. Kubota S, Ohsawa N, Takaku F: Effects of DL-alpha-difluoromethylornithine on the growth and metastasis of B16 melanoma in vivo. Int J Cancer 1987, 39:244–247.PubMed 55. Manni A, Washington S, Hu X, Griffith JW, Bruggeman R, Demers LM, Mauger D, Verderame MF: Effects of polyamine synthesis inhibitors on primary tumor features and metastatic PLEK2 capacity of human breast cancer cells. Clin Exp Metastasis 2005, 22:255–263.PubMed 56. MacDonald NJ, Steeg PS: Molecular basis of tumour metastasis. Cancer Surv 1993, 16:175–199.PubMed 57. Liotta LA, Rao CN, Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest 1983, 49:636–649.PubMed 58. Klymkowsky MW, Savagner P: Epithelial-mesenchymal transition: a cancer researcher’s conceptual friend and foe. Am J Pathol 2009, 174:1588–1593.PubMed 59. Pouyssegur J, Dayan F, Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006, 441:437–443.PubMed 60. Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266–276.PubMed 61. Harris AL: Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38–47.PubMed 62. Beavon IR: Regulation of E-cadherin: does hypoxia initiate the metastatic cascade? Mol Pathol 1999, 52:179–188.PubMed 63.